Mesoblast Ltd
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic… Read more
Mesoblast Ltd (MESO) - Net Assets
Latest net assets as of June 2025: $597.44 Million USD
Based on the latest financial reports, Mesoblast Ltd (MESO) has net assets worth $597.44 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($784.68 Million) and total liabilities ($187.24 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $597.44 Million |
| % of Total Assets | 76.14% |
| Annual Growth Rate | 18.74% |
| 5-Year Change | 2.76% |
| 10-Year Change | 13.12% |
| Growth Volatility | 274.19 |
Mesoblast Ltd - Net Assets Trend (2005–2025)
This chart illustrates how Mesoblast Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Mesoblast Ltd (2005–2025)
The table below shows the annual net assets of Mesoblast Ltd from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $597.44 Million | +24.38% |
| 2024-06-30 | $480.36 Million | -4.28% |
| 2023-06-30 | $501.84 Million | +0.96% |
| 2022-06-30 | $497.04 Million | -14.51% |
| 2021-06-30 | $581.40 Million | +5.84% |
| 2020-06-30 | $549.33 Million | +14.19% |
| 2019-06-30 | $481.05 Million | -11.90% |
| 2018-06-30 | $546.01 Million | +5.66% |
| 2017-06-30 | $516.77 Million | -2.16% |
| 2016-06-30 | $528.16 Million | -13.33% |
| 2015-06-30 | $609.36 Million | +6.58% |
| 2014-06-30 | $571.72 Million | -9.29% |
| 2013-06-30 | $630.27 Million | +31.62% |
| 2012-06-30 | $478.85 Million | -7.17% |
| 2011-06-30 | $515.84 Million | +1260.38% |
| 2010-06-30 | $37.92 Million | +47.03% |
| 2009-06-30 | $25.79 Million | -1.63% |
| 2008-06-30 | $26.22 Million | +27.64% |
| 2007-06-30 | $20.54 Million | +71.66% |
| 2006-06-30 | $11.97 Million | -37.89% |
| 2005-06-30 | $19.26 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mesoblast Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100943263100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.51 Billion | 252.55% |
| Other Comprehensive Income | $99.50 Million | 16.65% |
| Total Equity | $597.44 Million | 100.00% |
Mesoblast Ltd Competitors by Market Cap
The table below lists competitors of Mesoblast Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
RBL Bank Limited
NSE:RBLBANK
|
$1.94 Billion |
|
ITC HOTELS LIMITED
NSE:ITCHOTELS
|
$1.94 Billion |
|
Hyundai Autoever Corp
KO:307950
|
$1.94 Billion |
|
Danieli & C RSP
LSE:0N4I
|
$1.94 Billion |
|
Baoding Tianwei Baobian Electric Co Ltd
SHG:600550
|
$1.94 Billion |
|
NCC AB (publ)
PINK:NCCBF
|
$1.94 Billion |
|
SSR MINING INC. CDIS/1
F:ZSV1
|
$1.94 Billion |
|
Delek US Holdings Inc
F:DEH
|
$1.94 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mesoblast Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 480,355,000 to 597,442,000, a change of 117,087,000 (24.4%).
- Net loss of 102,142,000 reduced equity.
- New share issuances of 161,205,000 increased equity.
- Other comprehensive income increased equity by 21,196,000.
- Other factors increased equity by 36,828,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-102.14 Million | -17.1% |
| Share Issuances | $161.21 Million | +26.98% |
| Other Comprehensive Income | $21.20 Million | +3.55% |
| Other Changes | $36.83 Million | +6.16% |
| Total Change | $- | 24.38% |
Book Value vs Market Value Analysis
This analysis compares Mesoblast Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.94x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 40.56x to 2.94x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-06-30 | $0.36 | $14.53 | x |
| 2006-06-30 | $0.22 | $14.53 | x |
| 2007-06-30 | $0.38 | $14.53 | x |
| 2008-06-30 | $0.49 | $14.53 | x |
| 2009-06-30 | $0.48 | $14.53 | x |
| 2010-06-30 | $0.71 | $14.53 | x |
| 2011-06-30 | $9.59 | $14.53 | x |
| 2012-06-30 | $8.91 | $14.53 | x |
| 2013-06-30 | $11.72 | $14.53 | x |
| 2014-06-30 | $10.63 | $14.53 | x |
| 2015-06-30 | $11.33 | $14.53 | x |
| 2016-06-30 | $9.82 | $14.53 | x |
| 2017-06-30 | $9.61 | $14.53 | x |
| 2018-06-30 | $5.86 | $14.53 | x |
| 2019-06-30 | $9.73 | $14.53 | x |
| 2020-06-30 | $10.39 | $14.53 | x |
| 2021-06-30 | $9.61 | $14.53 | x |
| 2022-06-30 | $7.28 | $14.53 | x |
| 2023-06-30 | $5.98 | $14.53 | x |
| 2024-06-30 | $4.87 | $14.53 | x |
| 2025-06-30 | $4.95 | $14.53 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mesoblast Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -17.10%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -593.92%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.31x
- Recent ROE (-17.10%) is above the historical average (-20.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -7.63% | -292.39% | 0.02x | 1.11x | $-3.40 Million |
| 2006 | -69.36% | -294.09% | 0.17x | 1.37x | $-9.50 Million |
| 2007 | -42.49% | -519.74% | 0.08x | 1.03x | $-10.78 Million |
| 2008 | -38.38% | -1105.99% | 0.03x | 1.06x | $-12.68 Million |
| 2009 | -47.64% | -1379.29% | 0.03x | 1.05x | $-14.86 Million |
| 2010 | -38.98% | -268743.55% | 0.00x | 1.04x | $-18.57 Million |
| 2011 | 17.56% | 74.93% | 0.16x | 1.48x | $39.02 Million |
| 2012 | -14.86% | -185.86% | 0.05x | 1.50x | $-119.03 Million |
| 2013 | -9.78% | -214.21% | 0.03x | 1.40x | $-124.69 Million |
| 2014 | -14.16% | -311.62% | 0.03x | 1.57x | $-138.13 Million |
| 2015 | -19.59% | -502.64% | 0.02x | 1.67x | $-180.30 Million |
| 2016 | -0.78% | -9.70% | 0.06x | 1.30x | $-56.94 Million |
| 2017 | -14.86% | -3184.70% | 0.00x | 1.27x | $-128.49 Million |
| 2018 | -6.46% | -203.51% | 0.03x | 1.27x | $-89.89 Million |
| 2019 | -18.67% | -537.01% | 0.03x | 1.36x | $-137.90 Million |
| 2020 | -14.19% | -242.38% | 0.04x | 1.34x | $-132.87 Million |
| 2021 | -17.00% | -1325.25% | 0.01x | 1.28x | $-156.95 Million |
| 2022 | -18.38% | -894.59% | 0.02x | 1.33x | $-141.05 Million |
| 2023 | -16.32% | -1091.71% | 0.01x | 1.33x | $-132.07 Million |
| 2024 | -18.31% | -1490.27% | 0.01x | 1.39x | $-135.99 Million |
| 2025 | -17.10% | -593.92% | 0.02x | 1.31x | $-161.89 Million |
Industry Comparison
This section compares Mesoblast Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mesoblast Ltd (MESO) | $597.44 Million | -7.63% | 0.31x | $1.94 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |